Ezurpimtrostat
Small molecule
Also known as GNS561
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05874414 NCT05874414 · Cholangiocarcinoma with KRAS Mutation Registry: NCT05874414 | 1/2 | Incidence of dose limiting toxicity (DLT) of GNS561 with trametinib (Phase 1b) (At the end of Cycle 1 (each Cycle is 21 days)); Objective response rate (ORR) of the combination of GNS561 with trametinib (Phase 2a) (Up to 11 months (estimated)) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ezurpimtrostat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.